title: Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.
abstract: In this study, we combined the dipeptidyl peptidase-4 inhibitor sitagliptin with the antidiabetic drug mangiferin to examine the effects on active glucagon-like peptide-1 (GLP-1) and glucose tolerance in streptozotocin-diabetic rats. Active GLP-1 levels were measured by an ELISA kit. Insulin levels were measured by an RIA kit. Islet morphology was determined by double immunolabeling. Sitagliptin (1 mg/kg) or mangiferin (20 mg/kg) single treatment improved glucose tolerance during an oral glucose tolerance test. In addition, the combination therapy improved glucose tolerance with an increase in plasma insulin level and active GLP-1 levels. Islets from combination-treated diabetic rats had markedly increased β-cell/islet area ratio compared with islets from the diabetic or single-treatment rats. In conclusion, these results indicate that the combination therapy is useful as a therapeutic agent for impaired glucose tolerance and type 2 diabetes.
authors.affiliation: Department of Pharmacy, Chengdu Military General Hospital, Chengdu, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Hou
authors.forename: Dezhi
authors.initials: D
authors.lastname: Zheng
authors.forename: Kaihua
authors.initials: K
authors.lastname: Fan
authors.forename: Botao
authors.initials: B
authors.lastname: Yu
authors.forename: Wenjing
authors.initials: W
authors.lastname: Xiao
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
authors.forename: Weihua
authors.initials: W
authors.lastname: Jin
authors.forename: Yonghong
authors.initials: Y
authors.lastname: Tan
authors.forename: Juan
authors.initials: J
authors.lastname: Wu
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D018149:Glucose Intolerance / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D007515:Islets of Langerhans / Q000473:pathology; D008297:Male; D011719:Pyrazines / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068900:Sitagliptin Phosphate; D013311:Streptozocin; D014230:Triazoles / Q000008:administration & dosage*; D044004:Xanthones / Q000008:administration & dosage*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007328:Insulin; D011719:Pyrazines; D014230:Triazoles; D044004:Xanthones; C013592:mangiferin; D013311:Streptozocin; D052216:Glucagon-Like Peptide 1; D000068900:Sitagliptin Phosphate